Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label single-arm study of ocrelizumab in early relapsing remitting multiple sclerosis
2016-002937-31Phase 3Completed
- Sponsor
- Roche
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of ocrelizumab in multiple sclerosis (MS), sponsored by Roche. Primary endpoint: Disease progression. Started Apr 2017; status: completed.
02
Drugs
ocrelizumab
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2016-002937-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002937-31.